J&J expands dermatology portfolio with $850m Proteologix acquisition – Pharmaceutical Technology
J&J will gain access to Proteologix’s PX128 and PX130 for the treatment of atopic dermatitis. Credits: Skorzewiak/Shutterstock.com In a bid to solidify its footing in